Is there a tablet form of Mounjaro? The facts on tirzepatide and oral options

The biggest misconception: an oral tirzepatide tablet is not yet real

Many people searching for a tablet form of Mounjaro have seen press coverage of Eli Lilly's work on oral tirzepatide. The confusion is understandable. Lilly has been developing an oral version and early trial data has been reported in the medical press, but as of summer 2026 no oral tirzepatide product holds a licence in the UK, the EU or the US. What is licensed, tested and dispensable is tirzepatide in its existing injection form only.

The KwikPen delivers four weekly doses in a single device. Treatment typically begins at 2.5 mg, a dose designed to let your system settle before the prescriber considers stepping up. That titration process matters: the injection route gives prescribers precise control over absorbed dose, which is harder to replicate in a tablet because the gut's enzymes and stomach acid break down peptide molecules quickly. That is precisely the engineering challenge Lilly is still solving for tirzepatide. You can read more about how tirzepatide works as a dual GIP and GLP-1 receptor agonist on our dedicated overview page.

So if a website is selling what it calls an oral or tablet form of Mounjaro, that product does not exist as a licensed medicine, and our page on Mounjaro in tablet form explains the current situation in full. The MHRA has warned repeatedly about unlicensed products circulating online, and the risks of consuming an unverified compound are serious. Worth checking: the GPhC pharmacy register lets you confirm any online pharmacy's legitimacy in under a minute.

What the oral Wegovy tablet actually is, and where it fits

The closest thing to an oral weight-loss injection alternative that genuinely exists in the UK is the Wegovy tablet. The MHRA granted it marketing authorisation on 11 June 2026, making it the first oral GLP-1 medicine licensed for weight management in the UK and the first in Europe. It contains semaglutide co-formulated with an absorption enhancer (SNAC) that helps the molecule survive the stomach and enter the bloodstream.

The dosing ladder runs 1.5 mg, 4 mg, 9 mg and then the 25 mg maintenance dose, with at least a month between each step. That escalation is set by your prescriber, not by you. Crucially, taking the tablet correctly matters more than with an injection: it must be swallowed whole first thing in the morning, on a completely empty stomach, with a small amount of plain water, and you then need to wait at least 30 minutes before eating, drinking anything else (coffee included) or taking other oral medicines. Miss that window and absorption drops sharply.

In the OASIS 4 phase-3 trial (307 adults, 64 weeks) participants on oral semaglutide lost around 13.6% of body weight on average, compared with roughly 2.4% on placebo. Among those who followed the regimen precisely, average weight loss was closer to 17%. That adherence gap is real and something our prescribers discuss with patients who are weighing up injection versus tablet. One practical advantage the tablet has is storage: no refrigeration needed, which makes it simpler for people who travel regularly or who simply find a weekly injection daunting.

Mounjaro injection versus oral semaglutide: what the evidence actually shows

If your interest in a tablet stems from needle anxiety, that is a very common concern and one worth raising openly during your consultation. If you have also been wondering whether there is a pill form of tirzepatide, our dedicated page addresses that question directly. The SURMOUNT-1 trial, published in the New England Journal of Medicine, found that tirzepatide at 15 mg produced average body-weight reductions of around 20–21% over 72 weeks in adults with obesity. The SURMOUNT-5 head-to-head trial (2025, also published in the NEJM) showed tirzepatide produced greater average weight loss than semaglutide 2.4 mg injection over the same period.

Oral semaglutide's trial figure of 13.6% average loss sits below that, though the comparison is not head-to-head and involves different populations, durations and doses. NICE's appraisal of tirzepatide (TA1026, published December 2024) noted indirect comparisons favouring tirzepatide over semaglutide for weight loss. For more detail on how the two medicines stack up, our page on Mounjaro for weight management sets out the evidence in full.

Which option fits your situation is a clinical decision. Both are prescription-only medicines. Both require a prescriber to review your health history, current medicines and BMI before anything is issued. If spreading the cost matters to you, our page on Mounjaro on finance sets out the payment options available.

How a nume clinical review works if you want to explore your options

Needle aversion, tablet preference, questions about which medicine suits a particular health background, concerns about timing doses around holidays or a busy schedule like a payday week when you might be travelling, these are exactly the conversations a prescriber should have with you before you start any treatment. A consultation at nume is free. Your answers are reviewed the same day by a GPhC-registered Independent Prescriber, a real clinician who reads your form personally rather than an automated system passing you through a checklist.

Identity and weight are verified before anything is dispensed. If treatment is clinically appropriate and you order before midday on a working day, your medication is dispatched the same day and delivered free the next working day by DPD in plain packaging. There are no subscriptions and no auto-renewals: every repeat order is reviewed again by a prescriber. If you would like to understand more about how the service works, our about us page covers the clinical team, pharmacy registration and safety infrastructure in plain terms. You can also read more about available weight-loss treatment options before starting your consultation. Patients who are specifically curious about what a Mounjaro tablet would involve can find a clear explanation of the current development landscape on that page.